Monoclonal Antibody Program
A healthy immune system depends on inhibitory receptors. Inhibitory receptor medicines are currently at the forefront of cancer treatment due to the fact that overexpression of inhibitory receptors might impair T cell responses. Antibodies that target the inhibitory receptors PD1 and CTLA4 have demonstrated encouraging effects in a number of malignancies in recent years. However, due to...